SCHEMBL4275053

SCHEMBL4275053

CC(C)[Si](OCC(O)CNC(=O)OC(C)(C)C)(C(C)C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
SERPINE1 P05121 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
PCSK9 Q8NBP7 1/20 0.36
CYP2D6 P10635 1/20 0.36
CTSS P25774 3/20 0.36
CTSK P43235 3/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
SYK P43405 1/20 0.34
ADRB2 P07550 1/20 0.33
HTR1A P08908 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272756 1.00 MEN1 (0.39) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4272751 1.00 MEN1 (0.39) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4269122 0.82 SERPINE1 (0.41) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4269113 0.82 SERPINE1 (0.41) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4040354 0.82 SERPINE1 (0.38) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4269116 0.82 SERPINE1 (0.41) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL4040364 0.82 SERPINE1 (0.38) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL25400155 0.82 SERPINE1 (0.40) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL6854629 0.82 SERPINE1 (0.40) MEN1GAAKMT2ATDP1SERPINE1
SCHEMBL30015389 0.82 SERPINE1 (0.40) MEN1GAAKMT2ATDP1SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615568-B2 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation ELI LILLY AND COMPANY (US) 2009-11-10 US disclosed
US-7615568-B2 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation ELI LILLY AND COMPANY (US) 2009-11-10 US disclosed
US-20080108594-A1 Antithrombotic Ethers ELI LILLY AND COMPANY (US) 2008-05-08 US disclosed
US-20080108594-A1 Antithrombotic Ethers ELI LILLY AND COMPANY (US) 2008-05-08 US disclosed
EP-1644334-B1 ANTITHROMBOTIC ETHERS LILLY CO ELI (US) 2008-01-02 EP disclosed
EP-1644334-A1 ANTITHROMBOTIC ETHERS Eli Lilly and Company (US) 2006-04-12 EP disclosed
WO-2004108677-A1 ANTITHROMBOTIC ETHERS ELI LILLY AND COMPANY (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108594-A1 Antithrombotic Ethers F11, SERPINC1, F2 MEN1 441/4885GAA 2082/4885KMT2A 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.